On June 18, 2019, the United States Food and Drug Administration granted accelerated approval to the PD-1 inhibitor pembrolizumab for use as a monotherapy in the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least 1 other line of therapy. This approval was […]

Chimeric antigen receptor (CAR)-modified T cells have become an important treatment option for some patients with hematologic malignancies, including non-Hodgkin lymphoma and acute leukemias. However, CAR T-cell treatment can be associated with cytokine release syndrome (CRS), which limits its utility by restricting administration only to experienced centers capable of managing this potentially fatal event. In […]